Telangiectasia macularis eruptiva perstans

a very rare skin disease. Some researchers consider it a rare subtype of cutaneous mastocytosis. The lesions of TMEP typically appear as small, irregular red spots and brown widened blood vessels on the skin (telangiectasia) mostly located on the trunk, legs, and arms in a symmetrical pattern. The palms, soles and face are spared in most cases. In most cases, the lesions are not itchy and do not form blisters.

Also Known As:

Networked: 11 relevant articles (0 outcomes, 0 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Psoriasis (Pustulosis Palmaris et Plantaris)
2.	Systemic Mastocytosis
3.	Cutaneous Mastocytosis
4.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
5.	Telangiectasis (Telangiectasia)

Experts

1.	Barber, Cara: 1 article (06/2022)
2.	Song, Eingun James: 1 article (06/2022)
3.	Barsoum, Ramez: 1 article (02/2022)
4.	Lambie, Duncan: 1 article (02/2022)
5.	McMeniman, Erin: 1 article (02/2022)
6.	Mortimore, Alexandra Maria: 1 article (02/2022)
7.	Adamicová, Katarína: 1 article (09/2021)
8.	Burjanivová, Tatiana: 1 article (09/2021)
9.	Madleňák, Matúš: 1 article (09/2021)
10.	Malicherová, Bibiana: 1 article (09/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Telangiectasia macularis eruptiva perstans:

1.	Histamine (Histamine Dihydrochloride)FDA Link 02/01/1979 - "In addition, the patient had telangiectasia macularis eruptiva perstans and elevated histamine levels." 05/01/1995 - "Telangiectasia macularis eruptiva perstans, a rare form of cutaneous mastocytosis associated with elevated histamine excretion, has not previously been reported to complicate pregnancy. "
2.	Stem Cell FactorIBA 08/01/2023 - "In this article, we describe an unusual case of adult mastocytosis/telangiectasia macularis eruptiva perstans (TMEP) at the location of recovered HZ. Given that adult mastocytosis is thought to be caused by dysregulation of the mast cell growth factor receptor, the c-Kit proto-oncogene (CD117), and the fact that the varicella zoster virus-infected cutaneous lesions contain CD117-positive mast cells (CD117+MCs), we hypothesize that CD117+ MCs may be in charge of the local immunological response and cytokine release those results in TMEP after HZ."
3.	CytokinesIBA 08/01/2023 - "In this article, we describe an unusual case of adult mastocytosis/telangiectasia macularis eruptiva perstans (TMEP) at the location of recovered HZ. Given that adult mastocytosis is thought to be caused by dysregulation of the mast cell growth factor receptor, the c-Kit proto-oncogene (CD117), and the fact that the varicella zoster virus-infected cutaneous lesions contain CD117-positive mast cells (CD117+MCs), we hypothesize that CD117+ MCs may be in charge of the local immunological response and cytokine release those results in TMEP after HZ."
4.	InterferonsIBA 09/01/2021 - "Newly Developed Psoriasis in a Patient with Telangiectasia Macularis Eruptiva Perstans and Systemic Mastocytosis Treated with Interferon."
5.	Omalizumab (Xolair)FDA Link 02/01/2022 - "A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans."
6.	4-boronic acid benzophenoneIBA 01/01/2016 - "The clinical differential diagnosis included a benign pigmented purpura (BBP; Schamberg type), telangiectasia macularis eruptiva perstans, cutaneous T-cell lymphoma, essential telangiectasia, and cutaneous collagenous vasculopathy (CCV). "
7.	montelukast (Singulair)FDA Link 11/01/2009 - "Treatment of telangiectasia macularis eruptiva perstans with montelukast."
8.	risankizumabIBA 06/01/2022 - "Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans."

Therapies and Procedures

1.	Dye Lasers 01/01/1996 - "Treatment of telangiectasia macularis eruptiva perstans with the 585-nm flashlamp-pumped dye laser."
2.	Therapeutics 02/01/2022 - "Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. "
3.	PUVA Therapy 02/01/2010 - "Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy."
4.	Photochemotherapy (Photodynamic Therapy) 02/01/2010 - "We present the case of a 58-year-old woman who was diagnosed as having telangiectasia macularis eruptiva perstans (TMEP) and was successfully treated with PUVA photochemotherapy. "
5.	Lasers (Laser) 01/01/1998 - "We report a 20-year-old female patient with telangiectasia macularis eruptiva perstans characterised by telangiectatic macular lesions and episodic flushing, two lesions of which were successfully treated by laser. "